A major problem in cancer therapy is tumor drug resistance such as is found with antifolates (e.g., methotrexate fMTXI).
Introduction
Studies in normal and neoplastic human, and murine cells suggest that cellular resistance to methotrexate (MTX)' cytotoxicity is commonly due to a defect in MTX transport (1) (2) (3) (4) (5) (6) (7) (8) . Although transport defects have been implicated in development of resistance to MTX, specific mutations or changes in expression of transport molecules have not been described. At least two receptor systems seem to be involved in MTX transport. The reduced folate/ methotrexate transporter contained in murine L-1210 leukemia cells (7, 9, 10) and human CCRF-CEM lymphoblastic cells ( 1 1, 12) has an apparent molecular weight ranging from 36 to 78 kD on SDS-PAGE analysis (13) (14) (15) (16) and shows preference for reduced folates and equal affinity for MTX. The second folate/MTX transport system consists of a membrane-bound folate receptor with high affinities for folates including folic acid. It is found in human nasopharyngeal epidermoid carcinoma (KB) cells, MA 104 monkey kidney cells, T47D human mammary carcinoma cells, L-1210 and CCRF-CEM cells, and its expression increases when cells are adapted to low folate concentrations (17) (18) (19) (20) (21) (22) (23) (24) . This folate receptor is a 40-kD glycoprotein and in some cell lines appears to be responsible for internalization of folates and methotrexate. The folate receptor cDNA has been cloned and described (25) (26) (27) (28) (29) (30) .
In preliminary studies ofKB cell sublines selected for MTX resistant phenotypes (31, 32) , expression of human folate receptor (hFR) mRNA and protein were frequently reduced in parallel with decreased MTX uptake. These results suggest that hFR is an important determinant in MTX resistance or sensitivity in these cells. A potential problem in the interpretation of such studies is that when drug resistant cell lines are produced, gene products other than the one of interest may be induced or inhibited and these secondary changes may contribute to the observed phenotype. To circumvent this potential problem and to study the role ofa single gene product (the human folate receptor) in MTX sensitivity, we introduced recombinant KB cell cDNA encoding the hFR into human mammary carcinoma (MCF-7) and Chinese hamster ovary (CHO) cells (cells which normally do not express detectable levels of hFR), and asked whether increased hFR expression leads to increased MTX sensitivity. We present data which demonstrate that stably transfected MCF-7 and CHO cells expressing increased levels of hFR grow better in physiologic folate Plasmid construction. The pRc/cytomegalovirus (CMV) vector (Invitrogen Corp., San Diego, CA) contains a cytomegalovirus promotor and a neomycin resistance gene. The cDNA encoding hFR (FR-PI0) was isolated from a placental cDNA GTl 1 library (Elwood, P. C., K. Price, Y. Saikawa, S. T. Page, P. Pacheco, and K.-N. Chung, manuscript in preparation) and subcloned at the EcoRI multiple cloning site (MCS) of pGEM4Z (Promega Corp.). The insert-purified FR-PlO cDNA containing EcoRI ends was blunt-ended using Klenow large fragment (33) . The HindIll linearized pRc/CMV expression vector was treated with Klenow large fragment and alkaline phosphatase, and vector was ligated with blunt-ended insert using T4 DNA ligase. Competent Escherichia coli (JM109) were transformed with the ligation mixture and recombinant plasmids were isolated by maxiprep kit (Qiagen, Inc., Chatsworth, CA). The sense orientation ofthe folate receptor cDNA in pRc/CMV vector (pRc/P1O) was verified by restriction enzyme digests. We designated the plasmid construct containing pRc/ CMV vector and the human nasopharyngeal epidermoid carcinoma (KB) cell folate receptor cDNA (FR-PI0) as pRc/ P10.
Transfection. For stable transfection ofMCF-7 and CHO cells with pRc/PlO, we used the calcium phosphate method (34) . MCF-7 and CHO cells were also transfected with pRc/ CMV vector only. We found that the wild type and neo control cells are identical in their phenotype. These wild type and transfected clones served as controls in our experiments. Stable transfectants ofMCF-7 cells and CHO cells were clonally selected in 1 mg/ml geneticin sulfate (antibiotic G418; Gibco Laboratories, Grand Island, NY) and 500 ug/ml G418, respectively, using cloning cylinders. 1,000 cells were plated per 10-cm tissue culture plates, and -10 clones were picked from each plate. Stable Immunoprecipitation of hFR. MCF-7 stable transfectants (designated as clones neo, A6, and A4) were plated in 3 ml of DMEM, containing 10% FCS, 100 U/ml penicillin, 100 Mg/ml streptomycin, 0.25 ,g/ml fungizone (PSF), and 200 Mg/ml G418, in 35-mm wells (Falcon Plastics, Cockeysville, MD) at 37°C, 5% CO2. Plating densities were adjusted so that cells were 75% confluent when we carried out the immunoprecipitation experiments. Cells were washed once with 2 ml media containing no methionine or cysteine (Gibco Laboratories), and incubated in 2 ml of the same media for 1 h at 37°C, 5% CO2. Newly synthesized proteins were radiolabeled by pulsing the cells in 1 ml ofthe same media containing 100 MCi [35S] methionine and 100 MACi
[35S]cysteine for 1 h at 37°C, 5% CO2. The cells were washed once (2 ml) in media containing added cold methionine (15 mg/liter; Gibco Laboratories) and cysteine (24 mg/liter; Gibco Laboratories), and proteins were chased in this complete media (2 ml) for 5 h at 37°C, 5% CO2. At the end ofthe chase period, cells were washed three times with (2 ml each) ice-cold PBS, pH 7.4 (10 mM Na-phosphate, 150 mM NaCl; Biofluids Inc., Rockville, MD). Cells were scraped into (5 ml) ice cold PBS, 20 mM EDTA, pH 7.4, and 0.3% PMSF, and centrifuged at 3,000 g for 15 min at 4°C. Cell pellets were resuspended in ice-cold (I ml) 10 mM potassium phosphate, pH 7.4, and freeze-thawed twice. Cell membranes were spun for 15 min at 13,000 g at 4°C. Membrane proteins were solubilized in 1 ml PBS containing 1% Triton X-100 (vol/vol) for 18 h at 40C on a shaking platform. (All subsequent steps were carried out in buffers containing PMSF). Debris was removed by centrifugation for 15 min at 13,000 g at 40C. Supernatant samples were used for immunoprecipitation as follows: Protein A-Sepharose (Sigma Chemical Co.) was prewashed in immunoprecipitation buffer (10 mM Tris, 150 mM NaCl, 2 mM EDTA, pH 7.4, and 1% Triton X-100) and Folic acid binding assay. Folic acid binding assays on detergent-solubilized protein extracts were carried out as previously described ( 19) .
Methotrexate transport studies. MCF-7 stable transfectants and KB cells were plated as described above (see folic acid binding assays). Cell monolayers were washed two times with (3 ml) ice-cold pH 4.5 saline and two times with (3 ml) ice-cold PBS, pH 7.4. For internalization of 3H-MTX, cells were incubated in 2 ml of prewarmed (370C) DMEM (without FCS or other additives), containing 50 Ag/ml BSA, and 2 AM
[3H]MTX, for 30 min at 370C, 5% Co2. To determine specific MTX internalization (pmol/mg protein), parallel experiments were performed in the presence of 500-fold excess cold MTX. To differentiate transport mediated by hFR from the reduced folate transporter, parallel experiments were run in the presence of molar (1 00-fold) excess of cold folic acid which inhibits transport via hFR. The monolayer was washed once with 2 ml ice-cold PBS (pH 7.5), once with 2 ml pH 4.5 saline to remove surface-bound 3H-MTX, and finally with 2 ml of ice-cold PBS (pH 7.5). Cells were solubilized as described above (see immunoprecipitation studies). Samples (500 Al) were added to 10 ml of liquid scintillation cocktail and counted on a liquid scintillation counter (Tri-carb; Packard Instrument Co., Inc., Downers Grove, IL) at -50% efficiency. The data reflect specific internalization of 3H-MTX, since in the presence of excess nonradiolabeled MTX, MTX internalization was < 10% of total uptake for all data points. Protein concentration in each solubilized sample was determined as described above. The 3H-MTX transport studies were carried out three separate times. Values from separate experiments varied by < 10%.
Methotrexate sensitivity. MCF-7 stable transfectants (clones neo, A4, and A6) and CHO stable transfectants (CHO, clones 1 and 2) were plated as described above (see growth studies). After 24 h (to allow the cells to attach to the plates), medium containing increasing concentrations of MTX (0-1,000 nM) was added. Cells were harvested 5 d later. Cells were rinsed twice with 3 ml cold PBS, and solubilized as described above (see immunoprecipitation studies). The protein concentration of each sample was determined as described above. The MTX sensitivity studies were carried out three separate times and the values from separate experiments varied by < 5%.
Results and Discussion
Previous studies (32) Fig. 2 . The A6 clone expressed the highest level and A4 clone expressed the next highest level of hFR.
To assess the hFR levels more quantitatively, the level of hFR transcripts expressed by stable MCF-7 transfectants were determined by slot blot analysis of total cellular RNA. Fig. 3 A shows that clones A6 and A4 express increased levels of hFR transcripts. As previously reported, MCF-7 cells transfected with pRc/CMV vector alone (neo clone) did not express detectable levels of hFR transcript, represented in Fig. 3 A as  "u.d." (undetectable) . Next we examined whether clones A6 and A4 expressing increased levels of hFR replicate faster than the neo clone in low concentrations of folates. We found a positive relationship between hFR expression levels and growth in low concentrations of folates as shown in Fig. 3 B. Stable transfectants expressing increased levels of hFR (A6 and A4) grew 3.2-and 2.8-fold faster than cells transfected with vector alone (neo) or parental MCF-7 cells (data not shown). Similar findings were recently reported (35) .
The hFR expressed by clones A6 and A4 is sorted to the plasma membrane and binds ligand. Fig. 4 A shows that clones A6 and A4 bind high levels of radiolabeled folic acid (iodinated, histamine derivative of folic acid) at the cell surface, at levels (50-70%) approaching that seen in KB cells (normally, a high hFR expressing cell line). Fig. 4 A also shows that the neo clone did not contain detectable levels of cell surface folic acid binding ("u.d."). We have also carried out our studies on the cell surface-binding of this radioligand for 30 min at 0°C and found no difference between surface-binding at 15 and 30 min (data not shown). We have performed preliminary ligandbinding studies using the physiological circulating form of folate (5-methyltetrahydrofolate) and observed identical results (data not shown). When compared to control cells (neo clone), the solubilized total cellular extracts of clones A6 and A4 also showed proportionate increases in their total folic acid binding capacity at levels (40-50%) approaching that seen in KB cells (data not shown).
To show that the folate receptor is functional at the cell surface in these transfectants, we measured specific internalization of [3H]methotrexate. As shown in Fig. 4 B, stable transfectants expressing elevated levels of hFR show increased 3H-MTX uptake when cultured in DMEM: clones A6 and A4 internalize 3.2-and 2.4-fold more 3H-MTX than cells mock transfected with vector alone (neo). Fig. 4 B also shows that MTX transport found in clones A6 and A4 are approaching levels found in KB cells which internalize 3.6-fold more 'H-MTX than the neo clone. Interestingly, the neo clone demonstrated folic acid insensitive MTX uptake consistent with the absence of cell surface folic acid binding. In contrast, MTX uptake by the A6 and A4 transfectants is inhibited by both cold MTX (> 90%) and folic acid (> 60%). The absence of cell surface folic acid binding and the lack of inhibition of MTX influx in the presence of excess folic acid suggest that MCF-7 cells have a hFR-independent method of accumulating MTX such as the reduced folate transporter (1) (2) (3) (4) (5) (6) (7) (8) . However, transfection of MCF-7 cells with hFR appears to further increase (2.4-and 3.2-fold) their ability to internalize additional MTX.
To determine whether the differences in MTX uptake are reflected in MTX cytotoxicity, growth inhibition in increasing concentrations ofMTX was measured for each transfectant. As shown in Fig. 5 A, clones A4 and A6 are 8-and 10-fold respectively more sensitive to MTX than cells mock transfected with vector alone (neo) and wild type MCF-7 cells (data not shown). These results also demonstrate that the growth of mock transfectants was not completely inhibited, even at MTX concentrations 100-fold greater than that which inhibited > 99% of the growth of clones A4 and A6. The experiments on the sensitivity to MTX were carried out for 5 d. We have found (Fig. 5, A and B) . However, in standard medium, we did not observe a difference in MTX sensitivity between neo and A4/A6 clones (data not shown). Since standard medium (e.g., RMEM) contains 2.2 AuM folic acid and since intracellular folate concentrations are a direct function of folate concentration in culture medium (36) , it is likely that the reduced MTX cytotoxicity that we observed in transfectants cultured in RMEM results from competitive inhibition of MTX transport by folic acid [which has a higher affinity than MTX for the hFR]. This effect of folic acid concentration on MTX cytotoxicity has also been observed in KB cells (36) .
In conclusion, we have established stable transfectants which express high levels of hFR, to levels approaching that found in KB cells. These clones show that in physiologic concentrations of folic acid, increased levels ofhFR expression are related to cell growth, folic acid binding and transport, MTX transport, and MTX sensitivity. We have also observed small but reproducible differences in the expression of hFR between clones A6 and A4 which are consistent with different biochemical assays for hFR function. Although it is possible that other factors may be different between these two clones and their controls, there appears to be a correlation between levels of hFR and function of the hFR.
